BGY-1601-VT

DRUG2 trials

Sponsors

Nexbiome Therapeutics, NEXBIOME THERAPEUTICS

Conditions

Bacterial VaginosisGynaecologicalVulvovaginal Candidiasis

Phase 1

Efficacy, Safety, and Dose-response of a Live Biotherapeutic Product in Women With Acute Vaginal Infection

Not yet recruitingNCT06450990

NEXBIOME THERAPEUTICSBacterial Vaginosis, Vulvovaginal Candidiasis

Start: 2024-07-08End: 2026-02-26Target: 165Updated: 2024-06-12

Efficacy, safety, and dose-response of a Live Biotherapeutic Product (BGY-1601-VT, vaginal tablet) as a first-line monotherapy in women with acute vaginal infection: a randomized, double-blind, placebo-controlled study

RecruitingCTIS2023-508958-26-00

Nexbiome TherapeuticsGynaecological

Start: 2024-10-16Target: 165Updated: 2026-01-26